This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 07
  • /
  • FDA approves Qwo (collagenase clostridium histolyt...
News

FDA approves Qwo (collagenase clostridium histolyticum-aaes) to treat cellulite in adult women.-Endo International.

Read time: 1 mins
Published:8th Jul 2020
Endo International plc announced that it received FDA approval of Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is the first FDA-approved injectable treatment for cellulite. While cellulite is known to be a multifactorial condition, a primary contributing factor is the fibrous connective tissue, called the "fibrous septae," which connect the skin perpendicularly to the fascia below.These fibrous septae tether the skin, drawing it downward and leading to a mattress-like appearance, commonly referred to as "dimpling." When injected into the treatment area, QWO is thought to release the fibrous septae enzymatically by specifically targeting Types 1 and 3 collagen, which may result in smoothing of the skin and an improved appearance of cellulite.
Condition: Cellulite
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.